RecruitingNot ApplicableNCT07027254

PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism

A Randomized Controlled Trial to Evaluate the Effect of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Patients With Primary Aldosteronism (The PETAL Trial)


Sponsor

Seoul National University Hospital

Enrollment

90 participants

Start Date

Jun 25, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This study is a randomized controlled trial to assess the clinical utility of gallium-68 pentixafor PET/CT in the management of primary aldosteronism (PA). We aim to evaluate whether the addition of 68Ga-pentixafor PET/CT to standard adrenal venous sampling (AVS) improves surgical outcomes in patients with unilateral PA.


Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This study is evaluating whether a special type of PET scan (using a tracer called Gallium-68 Pentixafor) can help surgeons make better decisions about which adrenal gland to remove in people with a condition called primary aldosteronism (where the adrenal glands produce too much of a hormone that raises blood pressure). **You may be eligible if:** - You are 19 or older - You have been diagnosed with primary aldosteronism - You have had a CT scan of your adrenal glands - You are willing to undergo surgery **You may NOT be eligible if:** - You are pregnant, breastfeeding, or may become pregnant - You are not willing to have surgery - The required PET scans or adrenal vein sampling cannot be done safely for you - You have had previous abdominal surgery on the same side as the planned adrenal removal Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TEST68Ga-pentixafor PET/CT

Diagnostic PET/CT imaging using gallium-68 labeled pentixafor to assess adrenal CXCR4 expression in patients with primary aldosteronism. The imaging is performed prior to treatment allocation and used to assist lateralization of aldosterone production when combined with adrenal venous sampling (AVS).


Locations(2)

Samsung Medical Center

Seoul, Gangnam-gu, South Korea

Seoul National University Hospital

Seoul, Jongno-gu, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07027254


Related Trials